RhoVac Cancer Peptide Vaccine RV001 kukhala Patent ndi Canadian Intellectual Property Office

Canada nthawi 2022-01-24, RhoVac, kampani mankhwala lolunjika pa chotupa immunology, analengeza kuti patent ntchito (No. 2710061) kwa khansa peptide katemera RV001 adzakhala ovomerezeka ndi Canadian Intellectual Property Office (CIPO).M'mbuyomu, kampaniyo idapeza ziphaso zokhudzana ndi RV001 ku United States, Europe ndi Japan.Kupereka kwa patent kumeneku kudzapereka chitetezo chokulirapo cha RV001 m'misika yayikulu ndikukweza zotchinga za kampaniyo.

Monga ntchito ya patent yomwe idaperekedwa kale, patent iyi imakhudza katemera wa khansa wa RV001 ndi mitundu yake, komanso kugwiritsidwa ntchito kwake pochiza/kupewa RhoC-yowonetsa khansa ya metastatic.Pakati pawo, RhoC ndi antigen-associated antigen (TAA) yomwe imawonetsedwa mopitilira muyeso mumitundu yosiyanasiyana yama cell chotupa.Ikaperekedwa, patent idzatha mu 2028-12 ndipo ikuyembekezeka kukulitsidwa mukalandira Satifiketi ya Chitetezo Chowonjezera (CSP).

01 Onilcamotide

Onilcamotide ndi katemera wa khansa wopangidwa ndi ma immunogenic peptides opangidwa kuchokera ku Ras homologous membala C (RhoC), yemwe amatha kusindikizidwa mu immune adjuvant montanide ISA-51, yokhala ndi zochita zolimbitsa thupi komanso zotsutsana ndi zotupa.Subcutaneous makonzedwe a Onilcamotide kumapangitsa kuti chitetezo cha m'thupi chikhazikitse kuyankha kwa cytotoxic T lymphocyte (CTL) ku maselo a chotupa a RhoC, potero kunamiza maselo otupa.

2020-11, RV001 idapatsidwa dzina la Fast Track ndi FDA.

02 Mayesero azachipatala

Mu 2018, mayeso achipatala a Phase I/IIa a Onilcamotide ochizira khansa ya prostate adavomerezedwa, ndipo odwala 21 onse adalembetsa.Zotsatira zinawonetsa kuti Onilcamotide inali yotetezeka komanso yolekerera.Kuphatikiza apo, odwala adapanga mayankho amphamvu komanso olimba a chitetezo chamthupi atalandira chithandizo.Mu 2021, kutsatiridwa kwa 19 mwa maphunzirowa, patatha zaka zitatu atamaliza kulandira chithandizo ndi RhoVac, adawonetsa kuti anthuwa analibe metastases kapena kulandira chithandizo china ndipo analibe kupitilira kwa prostate-specific antigen (PSA)..Mwa awa, maphunziro a 16 analibe PSA yodziwika, ndipo maphunziro atatu anali ndi PSA pang'onopang'ono.PSA ndi puloteni yopangidwa ndi prostate gland ndipo imagwiritsidwa ntchito poyang'anira momwe khansa ya prostate ikudziwika.

Mu 2019, chipatala cha RV001 Phase IIb BraVac (yosasinthika, yakhungu iwiri, yoyendetsedwa ndi placebo) idakhazikitsidwa kuti iwunikire momwe imagwirira ntchito popewa kapena kuchepetsa kukula kwa khansa ya prostate ya metastatic pambuyo pa opaleshoni/radiation.Chiyeso chachipatala cha IIb ichi ndi chapadziko lonse lapansi, kafukufuku wambiri wolembera anthu m'maiko 6 aku Europe (Denmark, Finland, Sweden, Belgium, Germany, ndi United Kingdom) ndi United States.Mlanduwo unamaliza kulemba anthu odwala mu 2021-09, ndipo anthu pafupifupi 175 adalembetsa, ndipo adzatha mu 2022H1.Kuphatikiza apo, RhoVac ikukonzekera kuchita kafukufuku wofufuza zachipatala kuti apereke umboni pakukulitsidwa kwa RV001 pazisonyezo.

Kuphatikiza apo, komiti yowunikira chitetezo idachitanso kuwunika kwakanthawi kwachitetezo cha RV001 mu 2021-07, ndipo palibe zovuta zosayembekezereka zomwe zidapezeka, zomwe zinali zogwirizana ndi gawo lapitalo I/II zotsatira zachipatala.